ASX:CUV Clinuvel Pharmaceuticals (CUV) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Clinuvel Pharmaceuticals Stock (ASX:CUV) 30 days 90 days 365 days Advanced Chart Get CUV alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume124,193 shsAverage VolumeN/AMarket Capitalization$563.18 millionP/E Ratio15.95Dividend Yield0.44%Price TargetN/AConsensus RatingN/A Company OverviewClinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. The company was founded in 1987 and is headquartered in Melbourne, Australia.Read More… Receive CUV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Clinuvel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address CUV Stock News HeadlinesClinuvel Pharmaceuticals Stock Price HistoryMay 28, 2025 | investing.comClinuvel Pharmaceuticals Limited: CLINUVEL recruits 200 patients in Phase III vitiligo trial CUV105May 7, 2025 | finanznachrichten.deDo You Believe In President Trump? Answer This 1 QuestionThey said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to Trump’s economic plan. But now there’s a way to protect your retirement without backing down. This free 2025 Wealth Protection Guide reveals how you can use a legal IRS loophole—nicknamed “Piggy Bank”—to shield your savings.June 3, 2025 | Colonial Metals (Ad)Biocurious: FDA approval remains the Holy Grail for ASX life science stocksMarch 18, 2025 | msn.comHigh Growth Tech Stocks In Australia For March 2025March 16, 2025 | finance.yahoo.comClinuvel Introduces Groundbreaking Vitiligo Program at the World’s Biggest Dermatology Meeting, AAD 2025March 4, 2025 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Mesoblast Limited (OtherMEOBF) and Clinuvel Pharmaceuticals Limited (OtherCLVLF)February 27, 2025 | markets.businessinsider.comASX Growth Companies With High Insider Ownership In January 2025January 27, 2025 | finance.yahoo.comSee More Headlines CUV Stock Analysis - Frequently Asked Questions What other stocks do shareholders of Clinuvel Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Clinuvel Pharmaceuticals investors own include Cochlear (COH), CSL (CSL), ResMed (RMD), ARB (ARB), Accent Group (AX1), Corporate Travel Management (CTD) and Mineral Resources (MIN). Industry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolASX:CUV CIKN/A Webwww.clinuvel.com Phone61 3 9660 4900FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)A$0.70 Trailing P/E Ratio15.95 Forward P/E RatioN/A P/E GrowthN/ANet Income$35.64 million Net Margins40.67% Pretax MarginN/A Return on Equity18.67% Return on Assets14.29% Debt Debt-to-Equity Ratio0.43 Current Ratio8.81 Quick Ratio10.03 Sales & Book Value Annual Sales$88.18 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow19.36 Book ValueA$4.02 per share Price / BookN/AMiscellaneous Outstanding Shares50,060,000Free FloatN/AMarket Cap$563.18 million OptionableNot Optionable Beta0.92 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (ASX:CUV) was last updated on 6/3/2025 by MarketBeat.com Staff From Our PartnersDo You Believe In President Trump? Answer This 1 QuestionThey said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to...Colonial Metals | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredDalio heeds Buffett’s warning… [$319 million stake in gold]Dalio bought a gold ETF… I don’t recommend that for the average retail investor. The real upside is in profita...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Social Security Changes No One’s Talking AboutWhile most Americans worry about their next Social Security check... something far bigger is happening behind ...Altimetry | SponsoredBanks aren’t ready for this altcoin—are you?I've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredThe DOJ Just Paved the Way for Account SeizuresWashington is running out of money…And guess where they'll look next? When governments go broke, they take ...Priority Gold | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Clinuvel Pharmaceuticals Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Clinuvel Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CUV Stock Free CUV Stock Alerts